| Literature DB >> 35631175 |
Annalisa Gastaldello1, Francesca Giampieri1,2, José L Quiles1,3, María D Navarro-Hortal3, Silvia Aparicio1,4, Eduardo García Villena1,5, Kilian Tutusaus Pifarre1,5, Rachele De Giuseppe6, Giuseppe Grosso7, Danila Cianciosi8, Tamara Y Forbes-Hernández3, Seyed M Nabavi9, Maurizio Battino1,8,10.
Abstract
Age-related macular degeneration (AMD) is a serious degenerative disease affecting the eyes, and is the main cause of severe vision loss among people >55 years of age in developed countries. Its onset and progression have been associated with several genetic and lifestyle factors, with diet appearing to play a pivotal role in the latter. In particular, dietary eating patterns rich in plant foods have been shown to lower the risk of developing the disease, and to decrease the odds of progressing to more advanced stages in individuals already burdened with early AMD. We systematically reviewed the literature to analyse the relationship between the adherence to a Mediterranean diet, a mainly plant-based dietary pattern, and the onset/progression of AMD. Eight human observational studies were analysed. Despite some differences, they consistently indicate that higher adherence to a Mediterranean eating pattern lowers the odds of developing AMD and decreases the risk of progression to more advanced stages of the disease, establishing the way for preventative measures emphasizing dietary patterns rich in plant-foods.Entities:
Keywords: Mediterranean diet; dietary pattern; drusen; eating pattern; eye disease; macular degeneration; maculopathy; plant-based diets; retinal disease
Mesh:
Year: 2022 PMID: 35631175 PMCID: PMC9144566 DOI: 10.3390/nu14102028
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Figure 1Schematic representation adapted from [43] of the processed followed to identify and select suitable studies according to the PRISMA guidelines.
Characteristics of the eight studies included in this review evaluating the association between the Mediterranean diet and AMD.
| Article | Period of Data Collection | Exposure and Outcome Assessments | Outcome and | Adjusted Confounders | OR or HR (95% CI) and | Study Quality | Notes (See Main Text for Further Comments) |
|---|---|---|---|---|---|---|---|
| › Mares et al. | › CAREDS baseline: 2001–2004; WHIOS baseline: 1994–1998 | › Validated, semiquantitative FFQ at WHIOS baseline (122 items) | › Early AMD in at least one eye ( | (a) Model 1: age, pack-years smoked, history of diabetes, AMD, CVD and HRT, and iris colour | › Model 1: | High (8) | › Selected participantshad intakes of lutein plus zeaxanthin that were above the 78th and below the 28th percentiles |
| › Merle et al. | › 13 years (enrolment 1992–1998) | › Validated, self-administered, semiquantitative FFQ (90 items) at AREDS baseline | › Progression to advanced AMD ( | › Model 1: age, sex, AREDS treatment, AMD grade at baseline, TEI | › Model 1: | High (7) | › Evaluation of the interaction between aMED score and genetic variations on risk of AMD (10 SNPs analysed in 7 different genes) |
| › Hogg et al. | › 2001–2002 | › Semiquantitative FFQ (130 goods) tailored to each country | › Presence of AMD: | › Model 1: unadjusted | › Model 1: | High (9) | › No association between MDS and prevalence of GA |
| › Nunes et al. | › 2012–2014 | › Validated FFQ (86 items) | › AMD: case group = 768 (control = 1224, age and sex-matched) | › Age, sex, BMI, abdominal perimeter, | › OR = 0.73 (0.58–0.93) | High (7) | › Food group analysis: |
| › Raimundo et al. | › 2012–2014 | › Same as Nunes et al. 2018 | › AMD: case group = 434 (control = 449, age and sex-matched) | › Age, sex, smoking, calories consumption | › OR = 0.62 (0.38–0.97) | High (7) | › Physical activity and fruit consumption were higher in controls ( |
| › Merle et al. | › RS-I: 170-item validated semiquantitative FFQ at baseline | › Progression to advanced AMD ( | › Model 1: unadjusted | › Model 1: | High (RS-I = 8; Alienor = 7) | › Association remain after adjustment for two AMD-related SNPs | |
| › Keenan et al. | › 13 years (median follow-up 10.2 years), enrolment AREDS 1992–1998; AREDS2 2006–2008 | › AREDS: 90-item, validated, semiquantitative FFQ at baseline | › Progression to advanced AMD (AREDS, | › Treatment assignment, age, sex, smoking, TEI, BMI (for AREDS only), and correlation between eyes | › Combined cohort: | High (8) | › Analysis of interaction between aMED and genotype: in AREDS, protective effect was present only in subject with one particular protective allele |
| › Merle et al. | › 13 years (enrolment from 1992 to 1998) | › Validated, self-administered, 90-item, semiquantitative FFQ at baseline | › Drusen size progression ( | › Age, sex, education, smoking, BMI, AREDS treatment, multivitamin | › HR = 0.83 (0.68–0.99) | High (8) | › Drusen = major hallmark of AMD |
Characteristics of the eight studies included in this review evaluating the association between the Mediterranean diet and age-related macular degeneration. Abbreviations: AMD: Age-related Macular Degeneration; aMED: alternative or alternate Mediterranean diet score; AREDS/AREDS2: Age-Related Eye Disease Study; BMI: body mass index; CAREDS: Carotenoids in Age-Related Eye Disease Study; CARMS: Clinical Age-Related Maculopathy Staging; CVD: cardiovascular disease; EUREYE: European Eye (study) [55]; FFQ: Food Frequency Questionnaire; GA: geographic atrophy; HR: Hazard Ratio; HEI: Healthy Eating Index; HRT: hormone replacement therapy; ICS: International Classification System; MDS: Mediterranean diet score; mediSCORE: Mediterranean score; ns: not significant; nvAMD: neovascular AMD; OR: Odds Ratio; RCT: randomised controlled trial; SNPs: single nucleotide polymorphisms; TEI: total energy intake; WARMGS: Wisconsin Age-Related Maculopathy Grading System; WHIOS: Women’s Health Initiative Observational Study [56]. Tertile: a statistical value of a data set representing one-third of a given population; quartile: a statistical value of a data set representing 25% of a given population. AMD grading systems employed in the studies: WARMGS: early AMD = absence of signs of advanced AMD and the presence of (1) soft indistinct or reticular drusen or (2) hard distinct or soft distinct drusen with pigmentary abnormalities. Late AMD = presence of either (1) geographic atrophy or (2) exudative AMD. Exudative AMD is defined as the presence of any of the following exudative lesions: pigment epithelial detachment or age-related retinal detachment, subretinal haemorrhage, subretinal scar (subretinal fibrous scar), or prior laser treatment for exudative AMD [57,58]. CARMS (Clinical Age-Related Maculopathy Staging) = no AMD (few small drusen, <63 μm, grade 1); early AMD (drusen within 63–124 μm, grade 2); intermediate AMD (large drusen ≥ 125 μm grade 3); GA (geographic atrophy, both central and noncentral, grade 4); neovascular disease (hemorrhagic retinal detachment, haemorrhage under the retina or retinal pigment epithelium, subretinal fibrosis, grade 5) [48]. ICS: grade 0 = macula free of drusen or pigmentary irregularities or with hard drusen (<63 μm) only; early AMD is subdivided as follows: grade 1 = soft distinct drusen (≥63 μm) or pigmentary abnormalities; grade 2 = soft indistinct drusen (≥125 μm) or reticular drusen only or soft distinct drusen (≥63 μm) with pigmentary abnormalities; grade 3 = soft indistinct drusen (≥125 μm) or reticular drusen with pigmentary abnormalities; advanced AMD = grade 4 = presence of nvAMD (presence of serous or hemorrhagic retinal or retinal pigment epithelial detachment, subretinal neovascular membrane, periretinal fibrous scar) or GA (well-demarcated area of retinal pigment atrophy with visible choroidal vessels). Large drusen (≥125 μm) in any grade of early AMD also is categorized as a separate outcome [59,60]. In Mares et al. [36], the classification was based on a modified WARMGS and was as follows: early AMD = presence of either (1) large drusen (≥1 large drusen (≥125 μm) or extensive intermediate drusen (area ≥ 360 μm when soft indistinct drusen are present or ≥650 μm when soft indistinct drusen are absent)) or (2) pigmentary abnormalities of the retinal pigment epithelium (an increase or decrease in pigmentation accompanied with ≥1 drusen (≥63 μm)). This manuscript only considered early AMD. In Merle et al. [50] the classification was as followed: 0 = no drusen or questionable drusen; 1 = small drusen (<63 μm); 2 = intermediate drusen (63–124 μm); 3 = large drusen (125–249 μm); 4 = very large drusen (≥250 μm).